Flying L Partners

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.

TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.

Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Surface Pharmaceuticals is an owner and operator of a pharmaceutical company intended to provide ophthalmology products. The company's medicines use topical formulations with the patented Klarity delivery vehicle, designed to protect and rehabilitate the ocular surface, enabling patients with dry eye disease to recover on time and properly.

CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.